# Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

> **NCT06519994** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 120 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Human Papillomavirus
- Cervical Precancer

## Interventions

- **DRUG:** Artesunate vaginal inserts
- **DRUG:** Placebo vaginal inserts

## Key facts

- **NCT ID:** NCT06519994
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-22
- **Primary completion:** 2026-04-08
- **Final completion:** 2026-04-08
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519994, "Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT06519994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*